Vaccine and assay development for nairoviral diseases by Gilbride, C

The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world by Sharpe, HR, Gilbride, C, Allen, E, Belij-Rammerstorfer, S, Bissett, C, Ewer, K, Lambe, T

A multi-filovirus vaccine candidate: Co-expression of ebola, Sudan, and Marburg antigens in a single vector by Sebastian, S, Flaxman, A, Cha, KM, Ulaszewska, M, Gilbride, C, Sharpe, H, Wright, E, Spencer, AJ, Dowall, S, Hewson, R, Gilbert, S, Lambe, T

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse by Flaxman, A, Sebastian, S, Appelberg, S, Cha, KM, Ulaszewska, M, Purushotham, J, Gilbride, C, Sharpe, H, Spencer, AJ, Bibi, S, Wright, D, Schmidt, I, Dowall, S, Easterbrook, L, Findlay-Wilson, S, Gilbert, S, Mirazimi, A, Lambe, T

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice by Spencer, AJ, McKay, PF, Belij-Rammerstorfer, S, Ulaszewska, M, Bissett, CD, Hu, K, Samnuan, K, Blakney, AK, Wright, D, Sharpe, HR, Gilbride, C, Truby, A, Allen, ER, Gilbert, SC, Shattock, RJ, Lambe, T

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials by Voysey, M, Flaxman, A, Aboagye, J, Aley, PK, Belij-Rammerstorfer, S, Bibi, S, Bittaye, M, Cappuccini, F, Charlton, S, Clutterbuck, EA, Davies, S, Dold, C, Edwards, NJ, Ewer, K, Faust, SN, Folegatti, PM, Fowler, J, Gilbride, C, Gilbert, SC, Godfrey, L, Hallis, B, Humphries, HE, Jenkin, D, Kerridge, S, Mujadidi, YF, Plested, E, Ramasamy, MN, Robinson, H, Sanders, H, Snape, MD, Song, R, Thomas, KM, Ulaszewska, M, Woods, D, Wright, D, Pollard, AJ, Lambe, T

ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models by Lambe, T, Spencer, AJ, Thomas, KM, Gooch, KE, Thomas, S, White, AD, Humphries, HE, Wright, D, Belij-Rammerstorfer, S, Thakur, N, Conceicao, C, Watson, R, Alden, L, Allen, L, Aram, M, Bewley, KR, Brunt, E, Brown, P, Cavell, BE, Cobb, R, Fotheringham, SA, Gilbride, C, Harris, DJ, Ho, CMK, Hunter, L, Kennard, CL, Leung, S, Lucas, V, Ngabo, D, Ryan, KA, Sharpe, H, Sarfas, C, Sibley, L, Slack, GS, Ulaszewska, M, Wand, N, Wiblin, NR, Gleeson, FV, Bailey, D, Sharpe, S, Charlton, S, Salguero, FJ, Carroll, MW, Gilbert, SC

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses by Barrett, J, Belij-Rammerstorfer, S, Dold, C, Ewer, KJ, Folegatti, PM, Gilbride, C, Halkerston, R, Hill, J, Jenkin, D, Stockdale, L, Verheul, MK, Aley, PK, Angus, B, Bellamy, D, Berrie, E, Bibi, S, Bittaye, M, Carroll, MW, Cavell, B, Clutterbuck, EA, Edwards, N, Flaxman, A, Fuskova, M, Gorringe, A, Hallis, B, Kerridge, S, Lawrie, AM, Linder, A, Liu, X, Madhavan, M, Makinson, R, Mellors, J, Minassian, A, Moore, M, Mujadidi, Y, Plested, E, Poulton, I, Ramasamy, MN, Robinson, H, Rollier, CS, Song, R, Snape, MD, Tarrant, R, Taylor, S, Thomas, KM, Voysey, M, Watson, MEE, Wright, D, Douglas, AD, Green, CM, Hill, AVS, Lambe, T, Pollard, AJ